| http://www.w3.org/ns/prov#value | - ???With cancer drugs, what I???m seeing is that the cost-effectiveness ratio, like life expectancy and quality of life, is not particularly good for many of the new drugs,??? says Cohen. ???For the most part Sutent, Nexavar, Tarceva, and a lot of other new drugs aren???t terrible, but their benefit is relatively marginal.
|
